Feasibility and therapeutic strategies of vaccines against Porphyromonas gingivalis

Expert Review of Vaccines

Volumn 9, Issue 2, 2010, Pages 193-208

  Jong, Rosa Am ^a   Van Der Reijden, Wil A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Capsule; Fimbriae; Gingipain; Immunization; Periodontitis; Porphyromonas gingivalis; Vaccine

Indexed keywords

DNA; HEMAGGLUTININ; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE; LIVE VACCINE; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN A; VACCINE;

ANTIGEN RECOGNITION; FEASIBILITY STUDY; FIMBRIA; GINGIVA PAIN; HUMAN; NONHUMAN; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; REVIEW; THERAPY; ANIMAL; BACTEROIDACEAE INFECTION; IMMUNOLOGY; MICROBIOLOGY;

ANIMALS; BACTEROIDACEAE INFECTIONS; HUMANS; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; VACCINES;

EID: 77950348503     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.156     Document Type: Review

References (117)

1. Rylev M, Kilian M. Prevalence and distribution of principal periodontal pathogens worldwide. J. Clin. Periodontol. 35(8 Suppl.), 346-361 (2008).
2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 366(9499), 1809-1820 (2005).
3. Paster BJ, Boches SK, Galvin JL et al. Bacterial diversity in human subgingival plaque. J. Bacteriol. 183(12), 3770-3783 (2001).
4. Griffen AL, Becker MR, Lyons SR, Moeschberger ML, Leys EJ. Prevalence of Porphyromonas gingivalis and periodontal health status. J. Clin. Microbiol. 36(11), 3239-3242 (1998).
5. Rodenburg JP, van Winkelhoff AJ, Winkel EG, Goene RJ, Abbas F, de Graff J. Occurrence of Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in severe periodontitis in relation to age and treatment history. J. Clin. Periodontol. 17(6), 392-399 (1990).
6. Lamont RJ, Jenkinson HF. Life below the gum line: pathogenic mechanisms of Porphyromonas gingivalis. Microbiol. Mol. Biol. Rev. 62(4), 1244-1263 (1998).
7. Haubek D, Ennibi OK, Poulsen K, Vaeth M, Poulsen S, Kilian M. Risk of aggressive periodontitis in adolescent carriers of the JP2 clone of Aggregatibacter (Actinobacillus) actinomycetemcomitans in Morocco: a prospective longitudinal cohort study. Lancet 371(9608), 237-242 (2008).
8. Ogawa T, Tarkowski A, McGhee ML et al. Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic infammatory tissue. J. Immunol. 142(4), 1150-1158 (1989).
9. Ogawa T, Kusumoto Y, Hamada S, McGhee JR, Kiyono H. Bacteroides gingivalis-specifc serum IgG and IgA subclass antibodies in periodontal diseases. Clin. Exp. Immunol. 82(2), 318-325 (1990).
10. Slots J, Listgarten MA. Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases. J. Clin. Periodontol. 15(2), 85-93 (1988).
11. Whitney C, Ant J, Moncla B, Johnson B, Page RC, Engel D. Serum immunoglobulin G antibody to Porphyromonas gingivalis in rapidly progressive periodontitis: titer, avidity, and subclass distribution. Infect. Immun. 60(6), 2194-2200 (1992).
12. Okuda K, Kato T, Naito Y et al. Protective effcacy of active and passive immunizations against experimental infection with Bacteroides gingivalis in ligated hamsters. J. Dent. Res. 67(5), 807-811 (1988).
13. Chen PB, Neiders ME, Millar SJ, Reynolds HS, Zambon JJ. Effect of immunization on experimental Bacteroides gingivalis infection in a murine model. Infect. Immun. 55(10), 2534-2537 (1987).
14. Genco CA, Kapczynski DR, Cutler CW, Arko RJ, Arnold RR. Infuence of immunization on Porphyromonas gingivalis colonization and invasion in the mouse chamber model. Infect. Immun. 60(4), 1447-1454 (1992).
15. Kesavalu L, Ebersole JL, Machen RL, Holt SC. Porphyromonas gingivalis virulence in mice: induction of immunity to bacterial components. Infect. Immun. 60(4), 1455-1464 (1992).
16. Ebersole JL, Brunsvold M, Steffensen B, Wood R, Holt SC. Effects of immunization with Porphyromonas gingivalis and Prevotella intermedia on progression of ligature-induced periodontitis in the nonhuman primate Macaca fascicularis. Infect. Immun. 59(10), 3351-3359 (1991).
17. Persson GR, Engel D, Whitney C et al. Immunization against Porphyromonas gingivalis inhibits progression of experimental periodontitis in nonhuman primates. Infect. Immun. 62(3), 1026-1031 (1994).
18. Giardino A, Ebersole JL, Holt SC. Characteristics of systemic antibody responses of nonhuman primates following active immunization with Porphyromonas gingivalis, Prevotella intermedia and Bacteroides fragilis. Oral Microbiol. Immunol. 11(2), 79-87 (1996).
19. Cox SE, Holt SC, Ebersole JL. Characteristics of systemic antibody responses of nonhuman primates to cell envelope and cell wall antigens from periodontal pathogens. Oral Microbiol. Immunol. 12(4), 204-211 (1997).
20. Ebersole JL, Bauman GR, Cox O'Dell SE, Giardino A. Evidence for serum immunoglobulin G (IgG) antibody responses in Macaca fascicularis identifed by monoclonal antibodies to human IgG subclasses. Oral Microbiol. Immunol. 12(4), 193-203 (1997).
21. Holt SC, Kesavalu L, Walker S, Genco CA. Virulence factors of Porphyromonas gingivalis. Periodontol. 2000 20, 168-238 (1999).
22. van Winkelhoff AJ, Appelmelk BJ, Kippuw N, de Graaff J. K-antigens in Porphyromonas gingivalis are associated with virulence. Oral Microbiol. Immunol 8(5), 259-265 (1993).
23. Laine ML, Appelmelk BJ, van Winkelhoff AJ. Novel polysaccharide capsular serotypes in Porphyromonas gingivalis. J. Periodontal Res. 31(4), 278-284 (1996).
24. Jones C. Vaccine based on the cell surface carbohydrates of pathogenic bacteria. Academia Brasileira de Ciências 77(2), 293-324 (2005).
25. Nagasawa T, Aramaki M, Takamatsu N, Koseki T, Kobayashi H, Ishikawa I. Oral administration of Porphyromonas gingivalis fmbriae with cholera toxin induces anti-fmbriae serum IgG, IgM, IgA and salivary IgA antibodies. J. Periodontal Res. 34(3), 169-174 (1999).
26. Wu JJ, Huang DB, Pang KR, Tyring SK. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. J. Am. Acad. Dermatol. 50(4), 495-528; quiz 529-1432 (2004)
27. d'Empaire G, Baer MT, Gibson FC 3rd. The K1 serotype capsular polysaccharide of Porphyromonas gingivalis elicits chemokine production from murine macrophages that facilitates cell migration. Infect. Immun. 74(11), 6236-6243 (2006).
28. Laine ML, Appelmelk BJ, van Winkelhoff AJ. Prevalence and distribution of six capsular serotypes of Porphyromonas gingivalis in periodontitis patients. J. Dent. Res. 76(12), 1840-1844 (1997).
29. Amano A, Nakagawa I, Okahashi N, Hamada N. Variations of Porphyromonas gingivalis fmbriae in relation to microbial pathogenesis. J. Periodontal Res. 39(2), 136-142 (2004).
30. Brunner J, Crielaard W, van Winkelhoff AJ. Analysis of the capsular polysaccharide biosynthesis locus of Porphyromonas gingivalis and development of a K1-specifc polymerase chain reaction-based serotyping assay. J. Periodontal Res. 43(6), 698-705 (2008).
31. Gonzalez D, Tzianabos AO, Genco CA, Gibson FC 3rd. Immunization with Porphyromonas gingivalis capsular polysaccharide prevents P. gingivalis-elicited oral bone loss in a murine model. Infect. Immun. 71(4), 2283-2287 (2003).
32. Schifferle RE, Chen PB, Davern LB, Aguirre A, Genco RJ, Levine MJ. Modifcation of experimental Porphyromonas gingivalis murine infection by immunization with a polysaccharide-protein conjugate. Oral Microbiol Immunol. 8(5), 266-271 (1993).
33. Choi JI, Schifferle RE, Yoshimura F, Kim BW Capsular polysaccharide- fmbrial protein conjugate vaccine protects against Porphyromonas gingivalis infection in SCID mice reconstituted with human peripheral blood lymphocytes. Infect. Immun. 66(1), 391-393 (1998).
34. Martin JE, Pierson TC, Hubka S et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis. 196(12), 1732-1740 (2007).
35. Aduse-Opoku J, Slaney JM, Hashim A et al. Identifcation and characterization of the capsular polysaccharide (K-antigen) locus of Porphyromonas gingivalis. Infect. Immun. 74(1), 449-460 (2006).
36. Sims TJ, Schifferle RE, Ali RW, Skaug N, Page RC. Immunoglobulin G response of periodontitis patients to Porphyromonas gingivalis capsular carbohydrate and lipopolysaccharide antigens. Oral Microbiol Immunol. 16(4), 193-201 (2001).
37. Sims TJ, Ali RW, Brockman ES, Skaug N, Page RC. Antigenic variation in Porphyromonas gingivalis ribotypes recognized by serum immunoglobulin G of adult periodontitis patients. Oral Microbiol. Immunol. 14(2), 73-85 (1999).
38. Hirschfeld M, Weis JJ, Toshchakov V et al Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect. Immun. 69(3), 1477-1482 (2001).
39. Yoshimura A, Kaneko T, Kato Y, Golenbock DT, Hara Y. Lipopolysaccharides from periodontopathic bacteria Porphyromonas gingivalis and Capnocytophaga ochracea are antagonists for human Toll-like receptor 4. Infect. Immun. 70(1), 218-225 (2002).
40. Darveau RP, Pham TT, Lemley K et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. Infect. Immun. 72(9), 5041-5051 (2004).
41. Kikkert R, Laine ML, Aarden LA, van Winkelhoff AJ. Activation of Toll-like receptors 2 and 4 by Gram-negative periodontal bacteria. Oral Microbiol. Immunol. 22(3), 145-151 (2007).
42. Ogawa T. Chemical structure of lipid A from Porphyromonas (Bacteroides) gingivalis lipopolysaccharide. FEBS Lett. 332(1-2), 197-201 (1993).
43. Hajishengallis G, Martin M, Sojar HT et al. Dependence of bacterial protein adhesins on Toll-like receptors for proinfammatory cytokine induction. Clin. Diagn. Lab. Immunol. 9(2), 403-411 (2002).
44. Zhou Q, Desta T, Fenton M, Graves DT, Amar S. Cytokine profling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect. Immun. 73(2), 935-943 (2005).
45. Hajishengallis G, Tapping RI, Harokopakis E et al. Differential interactions of fmbriae and lipopolysaccharide from Porphyromonas gingivalis with the Toll-like receptor 2-centred pattern recognition apparatus. Cell. Microbiol. 8(10), 1557-1570 (2006).
46. Gaddis DE, Michalek SM, Katz J. Requirement of TLR4 and CD14 in dendritic cell activation by hemagglutinin B from Porphyromonas gingivalis. Mol. Immunol. 46(13), 2493-2504 (2009).
47. Chen PB, Davern LB, Schifferle R, Zambon JJ. Protective immunization against experimental Bacteroides (Porphyromonas) gingivalis infection. Infect. Immun. 58(10), 3394-3400 (1990).
48. Elkins KL, Stashak PW, Baker PJ. Prior exposure to subimmunogenic amounts of some bacterial lipopolysaccharides induces specifc immunological unresponsiveness. Infect. Immun. 55(12), 3085-3092 (1987).
49. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr. Infect. Dis. J. 27(3), 218-223 (2008).
50. Yoshimura F, Nishikata M, Suzuki T, Hoover CI, Newbrun E. Characterization of a trypsin-like protease from the bacterium Bacteroides gingivalis isolated from human dental plaque. Arch. Oral Biol. 29(7), 559-564 (1984).
51. Hamada N, Sojar HT, Cho MI, Genco RJ. Isolation and characterization of a minor fmbria from Porphyromonas gingivalis. Infect. Immun. 64(11), 4788-4794 (1996).
52. Yoshimura F, Takahashi Y, Hibi E, Takasawa T, Kato H, Dickinson DP. Proteins with molecular masses of 50 and 80 kilodaltons encoded by genes downstream from the fmbrilin gene (fmA) are components associated with fmbriae in the oral anaerobe Porphyromonas gingivalis. Infect. Immun. 61(12), 5181-5189 (1993).
53. Nishiyama S, Murakami Y, Nagata H, Shizukuishi S, Kawagishi I, Yoshimura F. Involvement of minor components associated with the FimA fmbriae of Porphyromonas gingivalis in adhesive functions. Microbiology 153(Pt 6), 1916-1925 (2007).
54. Yoshimura F, Murakami Y, Nishikawa K, Hasegawa Y, Kawaminami S. Surface components of Porphyromonas gingivalis. J. Periodontal Res. 44(1), 1-12 (2009).
55. Lee JY, Sojar HT, Bedi GS, Genco RJ. Porphyromonas (Bacteroides) gingivalis fmbrillin: size, amino-terminal sequence, and antigenic heterogeneity. Infect. Immun. 59(1), 383-389 (1991).
56. Nakagawa I, Amano A, Kimura RK, Nakamura T, Kawabata S, Hamada S. Distribution and molecular characterization of Porphyromonas gingivalis carrying a new type of fmA gene. J. Clin. Microbiol. 38(5), 1909-1914 (2000).
57. Nakagawa I, Amano A, Ohara-Nemoto Y et al. Identifcation of a new variant of fmA gene of Porphyromonas gingivalis and its distribution in adults and disabled populations with periodontitis. J. Periodontal Res. 37(6), 425-432 (2002).
58. Amano A, Nakagawa I, Kataoka K, Morisaki I, Hamada S. Distribution of Porphyromonas gingivalis strains with fmA genotypes in periodontitis patients. J. Clin. Microbiol. 37(5), 1426-1430 (1999).
59. Kato T, Kawai S, Nakano K et al. Virulence of Porphyromonas gingivalis is altered by substitution of fmbria gene with different genotype. Cell. Microbiol. 9(3), 753-765 (2007).
60. Ogawa T, Uchida H, Hamada S. Porphyromonas gingivalis fmbriae and their synthetic peptides induce proinfammatory cytokines in human peripheral blood monocyte cultures. FEMS Microbiol. Lett. 116(2), 237-242 (1994). (Pubitemid 24069304)
61. Harokopakis E, Hajishengallis G. Integrin activation by bacterial fmbriae through a pathway involving CD14, Toll-like receptor 2, and phosphatidylinositol-3-kinase. Eur. J. Immunol. 35(4), 1201-1210 (2005).
62. Hajishengallis G, Ratti P, Harokopakis E. Peptide mapping of bacterial fmbrial epitopes interacting with pattern recognition receptors. J. Biol. Chem. 280(47), 38902-38913 (2005).
63. Hajishengallis G, Wang M, Harokopakis E, Triantaflou M, Triantaflou K. Porphyromonas gingivalis fmbriae proactively modulate b2 integrin adhesive activity and promote binding to and internalization by macrophages. Infect. Immun. 74(10), 5658-5666 (2006).
64. Wang M, Shakhatreh MA, James D et al. Fimbrial proteins of Porphyromonas gingivalis mediate in vivo virulence and exploit TLR2 and complement receptor 3 to persist in macrophages. J. Immunol. 179(4), 2349-2358 (2007).
65. Evans RT, Klausen B, Sojar HT et al. Immunization with Porphyromonas (Bacteroides) gingivalis fmbriae protects against periodontal destruction. Infect. Immun. 60(7), 2926-2935 (1992).
66. Fan Q, Sims T, Sojar H, Genco R, Page RC. Fimbriae of Porphyromonas gingivalis induce opsonic antibodies that signifcantly enhance phagocytosis and killing by human polymorphonuclear leukocytes. Oral Microbiol. Immunol. 16(3), 144-152 (2001).
67. Yanagita M, Hiroi T, Kitagaki N et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fmbriae-specifc Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent infammatory cytokine production. J. Immunol. 162(6), 3559-3565 (1999).
68. Takahashi Y, Kumada H, Hamada N et al. Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fmbriae and recombinant cholera toxin B subunit. Oral Microbiol. Immunol. 22(6), 374-380 (2007).
69. Guo H, Wang X, Jiang G, Yang P. Construction of a sIgA-enhancing anti-Porphyromonas gingivalis FimA vaccine and nasal immunization in mice. Immunol. Lett. 107(1), 71-75 (2006).
70. Kawabata S, Terao Y, Fujiwara T, Nakagawa I, Hamada S. Targeted salivary gland immunization with plasmid DNA elicits specifc salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect. Immun. 67(11), 5863-5868 (1999).
71. Sharma A, Honma K, Evans RT, Hruby DE, Genco RJ. Oral immunization with recombinant Streptococcus gordonii expressing porphyromonas gingivalis FimA domains. Infect. Immun. 69(5), 2928-2934 (2001).
72. Yu F, Xu QA, Sun G, Chen W. CTLA4 targeting strategy in DNA vaccination against periodontitis. Med. Hypotheses 72(1), 41-42 (2009).
73. Murakami Y, Imai M, Nakamura H, Yoshimura F. Separation of the outer membrane and identifcation of major outer membrane proteins from Porphyromonas gingivalis. Eur. J. Oral Sci. 110(2), 157-162 (2002).
74. Nelson KE, Fleischmann RD, DeBoy RT et al. Complete genome sequence of the oral pathogenic Bacterium porphyromonas gingivalis strain W83. J. Bacteriol. 185(18), 5591-5601 (2003).
75. Ross BC, Czajkowski L, Vandenberg KL et al. Characterization of two outer membrane protein antigens of Porphyromonas gingivalis that are protective in a murine lesion model. Oral Microbiol. Immunol. 19(1), 6-15 (2004).
76. Shi X, Hanley SA, Faray-Kele MC et al. The rag locus of Porphyromonas gingivalis contributes to virulence in a murine model of soft tissue destruction. Infect. Immun. 75(4), 2071-2074 (2007).
77. Hall LM, Fawell SC, Shi X et al. Sequence diversity and antigenic variation at the rag locus of Porphyromonas gingivalis. Infect. Immun. 73(7), 4253-4262 (2005).
78. Slakeski N, Dashper SG, Cook P, Poon C, Moore C, Reynolds EC. A Porphyromonas gingivalis genetic locus encoding a heme transport system. Oral Microbiol. Immunol. 15(6), 388-392 (2000).
79. Dashper SG, Hendtlass A, Slakeski N et al. Characterization of a novel outer membrane hemin-binding protein of Porphyromonas gingivalis. J. Bacteriol. 182(22), 6456-6462 (2000).
80. Ross BC, Czajkowski L, Hocking D et al. Identifcation of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19(30), 4135-4142 (2001).
81. Hamada N, Watanabe K, Tahara T et al. The r40-kDa outer membrane protein human monoclonal antibody protects against Porphyromonas gingivalis-induced bone loss in rats. J. Periodontol. 78(5), 933-939 (2007).
82. Namikoshi J, Otake S, Maeba S, Hayakawa M, Abiko Y, Yamamoto M. Specifc antibodies induced by nasally administered 40-kDa outer membrane protein of Porphyromonas gingivalis inhibits coaggregation activity of P. gingivalis. Vaccine 22(2), 250-256 (2003).
83. Maeba S, Otake S, Namikoshi J et al. Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specifc antibodies which inhibit coaggregation by P. gingivalis. Vaccine 23(19), 2513-2521 (2005).
84. Koizumi Y, Kurita-Ochiai T, Yamamoto M. Transcutaneous immunization with an outer membrane protein of Porphyromonas gingivalis without adjuvant elicits marked antibody responses. Oral Microbiol. Immunol. 23(2), 131-138 (2008).
85. Momoi F, Hashizume T, Kurita-Ochiai T, Yuki Y, Kiyono H, Yamamoto M. Nasal vaccination with the 40-kilodalton outer membrane protein of Porphyromonas gingivalis and a nontoxic chimeric enterotoxin adjuvant induces long-term protective immunity with reduced levels of immunoglobulin E antibodies. Infect. Immun. 76(6), 2777-2784 (2008).
86. Zhang T, Hashizume T, Kurita-Ochiai T, Yamamoto M. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem. Biophys. Res. Commun. 390(3), 937-941 (2009).
87. Potempa J, Pike R, Travis J. The multiple forms of trypsin-like activity present in various strains of Porphyromonas gingivalis are due to the presence of either Arg-gingipain or Lys-gingipain. Infect. Immun. 63(4), 1176-1182 (1995).
88. Curtis MA, Kuramitsu HK, Lantz M et al. Molecular genetics and nomenclature of proteases of Porphyromonas gingivalis. J. Periodontal Res. 34(8), 464-472 (1999).
89. Grenier D, Roy S, Chandad F et al. Effect of inactivation of the Arg-and/or Lys-gingipain gene on selected virulence and physiological properties of Porphyromonas gingivalis. Infect. Immun. 71(8), 4742-4748 (2003).
90. Kuboniwa M, Amano A, Shizukuishi S. Hemoglobin-binding protein purifed from Porphyromonas gingivalis is identical to lysine-specifc cysteine proteinase (Lys-gingipain). Biochem. Biophys. Res. Commun. 249(1), 38-43 (1998).
91. Page RC, Lantz MS, Darveau R et al. Immunization of Macaca fascicularis against experimental periodontitis using a vaccine containing cysteine proteases purifed from Porphyromonas gingivalis. Oral Microbiol. Immunol. 22(3), 162-168 (2007).
92. Nakagawa T, Sims T, Fan Q et al. Functional characteristics of antibodies induced by Arg-gingipain (HRgpA) and Lys-gingipain (Kgp) from Porphyromonas gingivalis. Oral Microbiol. Immunol. 16(4), 202-211 (2001).
93. Gibson FC 3rd, Genco CA. Prevention of Porphyromonas gingivalis-induced oral bone loss following immunization with gingipain R1. Infect. Immun. 69(12), 7959-7963 (2001).
94. Genco CA, Odusanya BM, Potempa J, Mikolajczyk-Pawlinska J, Travis J. A peptide domain on gingipain R which confers immunity against Porphyromonas gingivalis infection in mice. Infect. Immun. 66(9), 4108-4114 (1998).
95. O'Brien-Simpson NM, Black CL, Bhogal PS et al. Serum immunoglobulin G (IgG) and IgG subclass responses to the RgpA-Kgp proteinase-adhesin complex of Porphyromonas gingivalis in adult periodontitis. Infect. Immun. 68(5), 2704-2712 (2000).
96. O'Brien-Simpson NM, Paolini RA, Reynolds EC. RgpA-Kgp peptide-based immunogens provide protection against Porphyromonas gingivalis challenge in a murine lesion model. Infect. Immun. 68(7), 4055-4063 (2000).
97. Rajapakse PS, O'Brien-Simpson NM, Slakeski N, Hoffmann B, Reynolds EC. Immunization with the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis protects against periodontal bone loss in the rat periodontitis model. Infect. Immun. 70(5), 2480-2486 (2002).
98. O'Brien-Simpson NM, Pathirana RD, Paolini RA et al. An immune response directed to proteinase and adhesin functional epitopes protects against Porphyromonas gingiva lis-induced periodontal bone loss. J. Immunol. 175(6), 3980-3989 (2005).
99. Frazer LT, O'Brien-Simpson NM, Slakeski N et al. Vaccination with recombinant adhesins from the RgpA-Kgp proteinase-adhesin complex protects against Porphyromonas gingivalis infection. Vaccine 24(42-43), 6542-6554 (2006).
100. Tam V, O'Brien-Simpson NM, PathiranaRD, Frazer LT, Reynolds EC. Characterization of T cell responses to the RgpA-Kgp proteinase-adhesin complexes of Porphyromonas gingivalis in BALB/c mice. J. Immunol. 181(6), 4150-4158 (2008).
101. Miyachi K, Ishihara K, Kimizuka R, Okuda K. Arg-gingipain A DNA vaccine prevents alveolar bone loss in mice. J. Dent. Res. 86(5), 446-450 (2007).
102. Yonezawa H, Ishihara K, Okuda K. Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model. Infect. Immun. 69(5), 2858-2864 (2001).
103. Nakayama K, Kadowaki T, Okamoto K, Yamamoto K. Construction and characterization of arginine-specifc cysteine proteinase (Arg-gingipain)- defcient mutants of Porphyromonas gingivalis. Evidence for signifcant contribution of Arg-gingipain to virulence. J. Biol. Chem. 270(40), 23619-23626 (1995).
104. Yonezawa H, Kato T, Kuramitsu HK, Okuda K, Ishihara K. Immunization by Arg-gingipain A DNA vaccine protects mice against an invasive Porphyromonas gingivalis infection through regulation of interferon-y production. Oral Microbiol Immunol. 20(5), 259-266 (2005).
105. Kuboniwa M, Amano A, Shizukuishi S, Nakagawa I, Hamada S. Specifc antibodies to Porphyromonas gingivalis Lys-gingipain by DNA vaccination inhibit bacterial binding to hemoglobin and protect mice from infection. Infect. Immun. 69(5), 2972-2979 (2001).
106. Han N, Whitlock J, Progulske-Fox A. The hemagglutinin gene A (hagA) of Porphyromonas gingivalis 381 contains four large, contiguous, direct repeats. Infect. Immun. 64(10), 4000-4007 (1996).
107. Katz J, Black K P, Michalek SM. Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model. Infect. Immun. 67(9), 4352-4359 (1999).
108. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J. Clin. Periodontol. 25(2), 134-144 (1998).
109. Rhemrev GE, Timmerman MF, Veldkamp I, Van Winkelhoff AJ, Van der Velden U. Immediate effect of instrumentation on the subgingival microfora in deep infamed pockets under strict plaque control. J. Clin. Periodontol. 33(1), 42-48 (2006).
110. Fujise O, Hamachi T, Inoue K, Miura M, Maeda K. Microbiological markers for prediction and assessment of treatment outcome following non-surgical periodontal therapy. J. Periodontol. 73(11), 1253-1259 (2002).
111. Magnusson I, Lindhe J, Yoneyama T, Liljenberg B. Recolonization of a subgingival microbiota following scaling in deep pockets. J. Clin. Periodontol. 11(3), 193-207 (1984).
112. van Winkelhoff AJ, Loos BG, van der Reijden WA, van der Velden U. Porphyromonas gingivalis, Bacteroides forsythus and other putative periodontal pathogens in subjects with and without periodontal destruction. J. Clin. Periodontol. 29(11), 1023-1028 (2002).
113. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21(Suppl. 2), S89-S95 (2003).
114. Yang QB, Martin M, Michalek SM, Katz J. Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis. Infect. Immun. 70(7), 3557-3565 (2002).
115. Dusek DM, Progulske-Fox A, Brown TA. Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin. Infect. Immun. 62(5), 1652-1657 (1994).
116. Isoda R, Simanski SP, Pathangey L, Stone AE, Brown TA. Expression of a Porphyromonas gingivalis hemagglutinin on the surface of a Salmonella vaccine vector. Vaccine 25(1), 117-126 (2007).
117. Shibata Y, Hosogi Y, Hayakawa M, Hori N, Kamada M, Abiko Y. Construction of novel human monoclonal antibodies neutralizing Porphyromonas gingivalis hemagglutination activity using transgenic mice expressing human Ig loci. Vaccine 23(29), 3850-3856 (2005).